Navigation Links
NW Bio Reaches Agreement With Convertible Note Holders
Date:3/10/2017

BETHESDA, Md., March 10, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that it has signed a Note Repurchase Agreement with a group of bondholders affiliated with Whitebox Advisors ("Whitebox"), holder of $11 million of NW Bio convertible senior notes.

With these Notes otherwise due today, as previously disclosed, NW Bio and Whitebox have negotiated a time payment approach tailored to the Company's development schedule with increasing periodic payments over the course of the next 4 months.  As part of the consideration for these adjustments, Whitebox also will be receiving NW Bio common stock.

The details of this cooperative arrangement are available in the 8-K filed by the Company this morning, which can be found on NW Bio's website at www.nwbio.com  

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.  The Company has a broad platform technology for DCVax dendritic cell-based vaccines.  The Company's lead program is a 331-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM).  GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease."  The Company is also pursuing a Phase I/II trial with DCVax-Direct for all types of inoperable solid tumor cancers.  It has completed the 40-patient Phase I portion of the trial, and is preparing for the Phase II portion.  The Company previously conducted a Phase I/II trial with DCVax-L for metastatic ovarian cancer together with the University of Pennsylvania.

Disclaimer 

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ability to fulfill its repayment obligations under the repurchase agreement, the risk of a default in its obligations under any installment under the agreement, the Company's ongoing ability to raise additional capital including to satisfy its obligations under the repurchase agreement, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's and Cognate's abilities to carry out the intended manufacturing expansions contemplated in the Cognate Agreements, risks related to the Company's ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nw-bio-reaches-agreement-with-convertible-note-holders-300421869.html


'/>"/>
SOURCE Northwest Biotherapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Indivumeds Cancer Database Reaches a Global Scale Through Partnership With the National Cancer Tissue Biobank (NCTB), Indian Institute of Technology Madras, Chennai, India
2. Purcell Julie & Lefkowitz LLP Is Investigating HedgePath Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
3. Kalorama: Medical Computed Tomography Systems Market Reaches $4.9 Billion
4. Cardinal Health Reaches Settlement With West Virginia
5. ResMed Reaches Historic One Billionth Night of Sleep Monitored
6. Kalorama: Infusion Pump Market Reaches $7 Billion
7. Kalorama: Global Medical Device Market Reaches $381 Billion
8. LIGHT FOR THE WORLD Reaches Milestone in Fight Against Trachoma in 2015: Almost Six Million People Prevented From Going Blind
9. FamilyWize Reaches $1 Billion Saved Milestone
10. Dipexium Pharmaceuticals Reaches 75% Enrollment Milestone in Pivotal Phase 3 Clinical Trials
11. Kalorama: Led by Self-Testing, Global POC Pregnancy and Fertility Testing Market Reaches $851 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
(Date:4/19/2017)... , April 19, 2017  New research provides evidence ... advanced Parkinson,s, according to a study released today that will ... Annual Meeting in Boston , April ... to the treatment of Parkinson,s disease, the oral drug levodopa ... life and longevity. But as the disease progresses, the effects ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ... HR decision-makers are preparing for how his administration could impact the employee benefits ... into what changes are most likely to make it through Congress. His discussion ...
(Date:4/25/2017)... NV (PRWEB) , ... April 25, 2017 , ... ... now choose a modern procedure that achieves results in a fraction of the ... in Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment ...
(Date:4/25/2017)... Minneapolis MN (PRWEB) , ... April 25, 2017 , ... ... patients and recreational users to dispensaries and head shops –can’t help but be heartened ... loathing for the tell-tale cannabis odor aptly described as “skunk smell.” At last ...
(Date:4/25/2017)... ... 2017 , ... There is no better place in South Florida to undergo ... the May issue of Consumer Reports focused on heart health. , The magazine ... and after coronary bypass and aortic valve replacement procedures. , Consumer Reports rated ...
(Date:4/24/2017)... FLORIDA (PRWEB) , ... April 24, 2017 , ... ... telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, ... LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed tablet ...
Breaking Medicine News(10 mins):